Running Trials in France? Know MR-001 & GDPR
When planning clinical trials in France, Sponsors must go beyond meeting the requirements of the General Data Protection Regulation (GDPR). Local rules add another layer of complexity—and overlooking them can stop a trial before it even begins. Even if a study is fully GDPR-compliant, Sponsors won’t receive the go-ahead from the French authorities unless they meet national data protection requirements, including, a submission to the CNIL, France’s data protection authority.
To help reduce the regulatory burden, the CNIL has introduced simplified pathways, that avoid the need for CNIL’s approval to conduct the research. One of the most commonly used is Methodology of Reference MR-001. Understanding whether your trial fits within the scope of MR-001 can make a meaningful difference—not just for compliance, but for the timeline of your study.
Why MR-001 Matters
MR-001 is a standardized framework issued by the CNIL to help Sponsors conduct interventional research, which includes a range of study types—from low-risk and low-constraint research to clinical drug trials, and even research involving the review of genetic characteristics —without having to undergo a full, detailed authorization process. If a trial fits within its parameters, Sponsors can simply submit a simplified declaration to the CNIL rather than apply for formal approval.
This is more than just a bureaucratic shortcut. By aligning with MR-001, Sponsors avoid delays and minimize administrative overhead, accelerating their study’s launch in France.
Understanding When MR-001 Applies
The methodology is tailored for interventional clinical research, which means the study must involve direct actions on participants—like administering a treatment or performing procedures—and take place in France.
MR-001 can only be used when the personal data collected is necessary for achieving the research objectives and the Sponsor adheres to strict conditions laid out in the methodology. This includes measures around data minimization, security, transparency, and data retention.
If your study doesn’t fully meet MR-001’s criteria—you’ll need to follow the more complex formal CNIL approval route.
Core Principles of MR-001
Sponsors following MR-001 are expected to apply GDPR principles rigorously, particularly when it comes to data protection and participant rights.
You’ll need to make sure that only strictly necessary personal data is collected and that participants are clearly informed—typically through the Informed Consent Form—about how their data will be used. This includes the identity of the Sponsor, the purpose of data processing, how long the data will be kept, who will receive it, and whether it will be transferred outside the EU.
Security is another cornerstone. Sponsors must apply measures such as encryption, pseudonymization, and strict access controls to protect personal data throughout the study. And once the research objectives have been met, the data should either be anonymized or securely deleted, unless there's a legal obligation to retain it longer.
Finally, proper documentation is essential. Even under the simplified framework, you must be able to demonstrate compliance—this means mapping data flows, maintaining records of processing activities, and in some cases, conducting a Data Protection Impact Assessment (DPIA).
What If Your Trial Falls Outside MR-001?
If your trial deviates from the MR-001 conditions, you’ll need to submit a formal request for authorization to the CNIL. This involves a more extensive process: a comprehensive DPIA, detailed justifications for any departures from the MR-001 standards, and evidence that participant rights remain protected throughout the study.
Naturally, this route is more time-consuming and resource-intensive. Moreover, the regulatory authority in France won’t approve the study unless it’s either declared compliant with MR-001 or has received formal approval from the CNIL. That’s why assessing MR-001 applicability early in the trial planning phase is not just helpful—it’s essential.
A Smarter Approach to Compliance
For Sponsors conducting clinical trials in France, the smartest move is to assess the study design against MR-001 requirements as early as possible—this step is essential for every clinical trial. Even if a Sponsor has previously submitted a declaration of compliance under MR-001, a fresh assessment must be done for each new study, as eligibility is study-specific.
If your trial aligns with MR-001, you can either submit a simplified declaration to the CNIL or rely on a previously submitted one. Once the declaration is in place, you can proceed with obtaining regulatory authority approval, benefiting from a faster and more predictable review process.
However, if the study falls outside the scope of MR-001, a formal CNIL authorization for the study is required. Only after receiving CNIL’s approval can the trial move forward with regulatory review.
At RD Privacy, we guide Sponsors through every step—from evaluating MR-001 eligibility to managing full CNIL submissions. Whether your trial qualifies for the simplified pathway or requires formal approval, we’re here to make the compliance process smooth, strategic, and fully aligned with regulatory expectations.
Need support? We’re just a message away.
Diana
